Covid-19 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CVD001 MIFTS: 44	Covid-19 Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Covid-19

MalaCards integrated aliases for Covid-19:

Name: Covid-19 ¹² ¹⁵

Wuhan Seafood Market Pneumonia Virus Infection ¹²

Wuhan Coronavirus Infection ¹²

2019 Novel Coronavirus ¹²

2019-Ncov Infection ¹²

Classifications:

MalaCards categories:
Global: Infectious diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0080600

Sources

Summaries for Covid-19

Disease Ontology : ¹² A Coronavirus infection that is characterized by fever, cough and shortness of breath and that has material basis in SARS-CoV-2.

MalaCards based summary : Covid-19, also known as wuhan seafood market pneumonia virus infection, is related to middle east respiratory syndrome and pneumonia. An important gene associated with Covid-19 is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Hematopoietic cell lineage and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Eprosartan and Nicardipine have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and liver.

Sources

Related Diseases for Covid-19

Diseases related to Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 951)

#	Related Disease	Score	Top Affiliating Genes
1	middle east respiratory syndrome	31.0	TMPRSS2 FURIN DPP4 CTSL ACE2
2	pneumonia	30.4	IL6 CRP CD8A ACE
3	viral pneumonia	30.3	IL6 CRP CD8A ACE2
4	pericardial effusion	30.1	IL6 CRP ACE
5	pericarditis	29.9	IL6 CRP ACE
6	purpura	29.9	IL6 CRP ACE
7	exanthem	29.8	IL6 CRP CD8A ACE
8	chickenpox	29.8	IL6 CRP CD8A
9	bacterial pneumonia	29.8	IL6 CRP CD8A
10	sleep apnea	29.8	IL6 CRP ACE
11	severe acute respiratory syndrome	29.7	TMPRSS2 IL6 FURIN CTSL CRP AGTR2
12	aspiration pneumonia	29.7	IL6 CRP ACE
13	sleep disorder	29.6	IL6 CRP ACE
14	pharyngitis	29.6	IL6 CRP CD8A
15	neuroretinitis	29.5	CRP ACE
16	hypersensitivity vasculitis	29.5	IL6 CRP ACE
17	viral exanthem	29.4	CRP CD8A
18	pulmonary disease, chronic obstructive	29.4	IL6 CRP CD8A ACE
19	bronchopneumonia	29.4	IL6 CRP CD8A
20	intermediate coronary syndrome	29.4	IL6 DPP4 CRP ACE
21	acute cystitis	29.4	IL6 DPP4 CRP ACE
22	juvenile rheumatoid arthritis	29.4	IL6 IL2RA CRP
23	acute interstitial pneumonia	29.3	CRP CD8A
24	thyroid gland disease	29.3	IL6 CRP ACE
25	orchitis	29.3	IL6 CRP CD8A
26	pneumocystosis	29.3	IL6 CRP CD8A
27	iridocyclitis	29.2	IL6 CRP ACE
28	uremia	29.2	IL6 CRP ACE
29	meningoencephalitis	29.2	IL6 CRP CD8A
30	celiac disease 1	29.2	IL6 IL2RA DPP4 CRP CD8A
31	retinal artery occlusion	29.2	IL6 CRP ACE
32	stroke, ischemic	29.2	IL6 CRP AGTR2 ACE2 ACE
33	carotid artery disease	29.2	IL6 CRP ACE
34	angioedema	29.1	DPP4 AGTR2 ACE
35	pulmonary tuberculosis	29.1	IL6 IL2RA CRP
36	syphilis	29.1	IL6 CRP CD8A ACE
37	prediabetes syndrome	29.0	IL6 DPP4 CRP ACE
38	aortic aneurysm, familial abdominal, 1	29.0	IL6 CTSL CRP ACE
39	systemic scleroderma	29.0	IL6 CRP CD8A ACE
40	intestinal obstruction	29.0	IL6 CRP CD8A
41	cellulitis	29.0	IL6 CRP CD8A
42	sarcoidosis 1	29.0	IL2RA CRP CD8A ACE
43	kidney disease	28.8	IL6 DPP4 CRP AGTR2 ACE2 ACE
44	myocardial infarction	28.7	IL6 DPP4 CRP AGTR2 ACE2 ACE
45	coronavirus infectious disease	28.6	TMPRSS2 IL6 FURIN DPP4 CTSL CRP
46	pancytopenia	28.3	IL6 IL2RA CRP CD8A ACE
47	hydronephrosis	28.1	IL6 CRP AGTR2
48	pulmonary fibrosis, idiopathic	28.0	IL6 CRP CD8A AGTR2 ACE
49	hypertension, essential	26.6	IL6 FURIN DPP4 CRP CD8A AGTR2
50	nosophobia	11.3

Graphical network of the top 20 diseases related to Covid-19:

Sources

Symptoms & Phenotypes for Covid-19

Sources

Drugs & Therapeutics for Covid-19

Drugs for Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 700)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Eprosartan

Approved

Phase 4

133040-01-4

5281037

Nicardipine

Approved, Investigational

Phase 4

55985-32-5

4474

Perindopril

Approved

Phase 4

107133-36-8, 82834-16-0

107807

Trandolapril

Approved

Phase 4

87679-37-6

5484727

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Lisinopril

Approved, Investigational

Phase 4

76547-98-3, 83915-83-7

5362119

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Felodipine

Approved, Investigational

Phase 4

72509-76-3

3333

Fosinopril

Approved

Phase 4

98048-97-6

55891

Olmesartan

Approved, Investigational

Phase 4

144689-24-7, 144689-63-4

158781 130881

Nimodipine

Approved, Investigational

Phase 4

66085-59-4

4497

Nifedipine

Approved

Phase 4

21829-25-4

4485

Metolazone

Approved

Phase 4

17560-51-9

4170

Chlorothiazide

Approved, Vet_approved

Phase 4

58-94-6

2720

Amlodipine

Approved

Phase 4

88150-42-9

2162

Verapamil

Approved

Phase 4

52-53-9

2520

Chlorthalidone

Approved

Phase 4

77-36-1

2732

Indapamide

Approved

Phase 4

26807-65-8

3702

Candesartan cilexetil

Approved

Phase 4

145040-37-5

2540

Bendroflumethiazide

Approved

Phase 4

73-48-3

2315

Quinapril

Approved, Investigational

Phase 4

85441-61-8

54892

Benazepril

Approved, Investigational

Phase 4

86541-75-5

5362124

Nitrendipine

Approved, Investigational

Phase 4

39562-70-4

4507

Clarithromycin

Approved

Phase 4

81103-11-9

84029

Oseltamivir

Approved

Phase 4

204255-11-8, 196618-13-0

65028

Bromhexine

Approved

Phase 4

3572-43-8

Ceftriaxone

Approved

Phase 4

73384-59-5

5361919 5479530

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

5754

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

5743

Ravulizumab

Approved, Investigational

Phase 4

1803171-55-2

Coal tar

Approved

Phase 4

8007-45-2

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Clavulanate

Approved, Vet_approved

Phase 4

58001-44-8

5280980

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Nadroparin

Approved, Investigational

Phase 4

Protein C

Approved

Phase 4

Tazobactam

Approved

Phase 4

89786-04-9

123630

Piperacillin

Approved

Phase 4

66258-76-2

43672

Ceftaroline fosamil

Approved, Investigational

Phase 4

229016-73-3

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Moxifloxacin

Approved, Investigational

Phase 4

354812-41-2, 151096-09-2

152946

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Metformin

Approved

Phase 4

657-24-9

14219 4091

Parathyroid hormone

Approved, Investigational

Phase 4

9002-64-6

Guanfacine

Approved, Investigational

Phase 4

29110-47-2

3519

Sertraline

Approved

Phase 4

79617-96-2

68617

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Interventional clinical trials:

(show top 50) (show all 2393)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection	Completed	NCT04345276	Phase 4	Danoprevir+Ritonavir
2	An Open Clinical Trial to Evaluate Ganovo（Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection	Completed	NCT04291729	Phase 4	Ganovo+ritonavir+/-Interferon nebulization
3	The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial	Recruiting	NCT04330300	Phase 4	Thiazide or Thiazide-like diuretics;Calcium Channel Blockers;ACE inhibitor;Angiotensin receptor blocker
4	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	Recruiting	NCT04355026	Phase 4	Bromhexine Oral Tablet and/or hydroxychloroquine tablet
5	Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease	Recruiting	NCT04394117	Phase 4	Angiotensin Receptor Blockers
6	Fluoxetine to Reduce Intubation and Death After COVID19 Infection	Recruiting	NCT04377308	Phase 4	Fluoxetine
7	A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment	Recruiting	NCT04384380	Phase 4	Hydroxychloroquine Sulfate 200 MG [Plaquenil]
8	Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection	Recruiting	NCT04411667	Phase 4	Octagam
9	A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting	Recruiting	NCT04370782	Phase 4	Hydroxychloroquine;Azithromycin;Zinc Sulfate;Doxycycline
10	Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications	Recruiting	NCT04331600	Phase 4	Chloroquine phosphate
11	Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial	Recruiting	NCT04353596	Phase 4	ACE inhibitor, angiotensin receptor blocker
12	Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)	Recruiting	NCT04367831	Phase 4	Enoxaparin Prophylactic Dose;Heparin Infusion;Heparin SC;Enoxaparin/Lovenox Intermediate Dose
13	Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19	Recruiting	NCT04325061	Phase 4	Dexamethasone
14	Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial	Recruiting	NCT04334629	Phase 4	Ibuprofen
15	Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE	Recruiting	NCT04373707	Phase 4	Enoxaparin;Enoxaparin
16	A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial	Recruiting	NCT04414267	Phase 4
17	A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.	Recruiting	NCT04326920	Phase 4	Sargramostim
18	Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome	Recruiting	NCT04341493	Phase 4	Nitazoxanide 500 MG;Hydroxychloroquine
19	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)	Recruiting	NCT04390464	Phase 4	Ravulizumab;Baricitinib
20	Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection	Recruiting	NCT04340557	Phase 4	Losartan
21	The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation	Recruiting	NCT04377750	Phase 4	Tocilizumab
22	Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial	Recruiting	NCT04405999	Phase 4	Bromhexine Hydrochloride
23	Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection	Recruiting	NCT04392531	Phase 4	Cyclosporine;Standard treatment
24	Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide	Recruiting	NCT04406246	Phase 4	Nitazoxanide 500Mg Oral Tablet
25	COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19	Recruiting	NCT04360824	Phase 4	Intermediate dose thromboprophylaxis;Standard of Care thromboprophylaxis
26	Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate	Recruiting	NCT04351191	Phase 4	Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
27	Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate	Recruiting	NCT04346667	Phase 4	Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
28	Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses	Recruiting	NCT04348370	Phase 4
29	PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease	Recruiting	NCT04335786	Phase 4	Valsartan (Diovan);Placebo oral tablet
30	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	Recruiting	NCT02735707	Phase 4	Fixed-duration Hydrocortisone;Shock-dependent hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin-tazobactam;Ceftaroline;Amoxicillin-clavulanate;Macrolide administered for 3-5 days;Macrolide administered for up to 14 days;Five-days oseltamivir;Ten-days oseltamivir;Lopinavir/ritonavir;Hydroxychloroquine;Hydroxychloroquine + lopinavir/ritonavir;Interferon-β1a;Anakinra;Fixed-duration higher dose Hydrocortisone;Tocilizumab;Sarilumab
31	A Post Marketing Surveillance (PMS) Study of RIXUBIS in India	Active, not recruiting	NCT03565237	Phase 4
32	Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease	Active, not recruiting	NCT04429867	Phase 4	Hydroxychloroquine;Placebo
33	A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]	Active, not recruiting	NCT03324880	Phase 4
34	Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection	Active, not recruiting	NCT04316377	Phase 4	Hydroxychloroquine Sulfate
35	Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial	Active, not recruiting	NCT04417335	Phase 4
36	A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis	Active, not recruiting	NCT03320070	Phase 4	Acthar Gel;Placebo
37	A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder	Active, not recruiting	NCT04085172	Phase 4	Guanfacine hydrochloride (SPD503);Atomoxetine hydrochloride
38	CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)	Active, not recruiting	NCT02915198	Phase 4	Metformin XR;Placebo
39	An Electrophysiological Predictor of SSRI Response in Veterans With PTSD	Active, not recruiting	NCT04183205	Phase 4	Placebo;sertraline
40	CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection	Active, not recruiting	NCT02667418	Phase 4	Fidaxomicin;Vancomycin with Taper/Pulse;Vancomycin
41	CSP #2008 - Pentoxifylline in Diabetic Kidney Disease	Active, not recruiting	NCT03625648	Phase 4	Pentoxifylline;Placebo
42	An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial	Enrolling by invitation	NCT04350671	Phase 4	Interferon Beta-1A;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine
43	Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial	Enrolling by invitation	NCT04350684	Phase 4	Umifenovir;Interferon-β 1a;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine;Standards of Care
44	Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury	Enrolling by invitation	NCT04397510	Phase 4	Heparin;0.9% Sodium-chloride
45	Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19	Enrolling by invitation	NCT04308317	Phase 4	Tetrandrine
46	Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).	Not yet recruiting	NCT04260594	Phase 4	Arbidol
47	Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes	Not yet recruiting	NCT04341935	Phase 4	Linagliptin;Insulin regimen
48	Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection	Not yet recruiting	NCT04350086	Phase 4	Treatment with Dexmedetomidine
49	The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients	Not yet recruiting	NCT04345887	Phase 4	Spironolactone 100mg;Placebo oral tablet
50	Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients	Not yet recruiting	NCT04411446	Phase 4	Vitamin D;Placebo

Search NIH Clinical Center for Covid-19

Sources

Genetic Tests for Covid-19

Sources

Anatomical Context for Covid-19

MalaCards organs/tissues related to Covid-19:

⁴⁰

Testes, Lung, Liver, Kidney, Heart, Brain, Skin

Sources

Publications for Covid-19

Articles related to Covid-19:

(show top 50) (show all 22613)

#	Title	Authors	PMID	Year
1	A letter to the editor: the impact of COVID-19 on intercalating and non-clinical medical students in the UK. ⁶¹	Abedi M...Abedi D	32449490	2020
2	The COVID-19 pandemic and international federation of medical students' association exchanges: thousands of students deprived of their clinical and research exchanges. ⁶¹	Bentata Y	32552464	2020
3	Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. ⁶¹	Chen JH...To KK	32459137	2020
4	Laboratory diagnosis of emerging human coronavirus infections - the state of the art. ⁶¹	Loeffelholz MJ...Tang YW	32196430	2020
5	ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. ⁶¹	Suo T...Chen Y	32438868	2020
6	Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. ⁶¹	Baek YH...Song MS	32306853	2020
7	Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. ⁶¹	Meng J...Zhang G	32228222	2020
8	Being a front-line dentist during the Covid-19 pandemic: a literature review. ⁶¹	Fallahi HR...Cheshmi B	32341913	2020
9	COVID-19 pandemic - an African perspective. ⁶¹	Lone SA...Ahmad A	32458760	2020
10	COVID-19: What implications for sexual and reproductive health and rights globally? ⁶¹	Hussein J	32191167	2020
11	What lies in the year ahead for medical education? A medical student's perspective during the COVID-19 pandemic. ⁶¹	Raymond-Hayling O	32544000	2020
12	Access to later abortion in the United States during COVID-19: challenges and recommendations from providers, advocates, and researchers. ⁶¹	Ruggiero S...Chandrasekaran S	32460663	2020
13	The burden, admission, and outcome of COVID-19 in Africa: protocol for a systematic review and meta-analysis. ⁶¹	Tadesse DB...Demoz GT	32538295	2020
14	Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. ⁶¹	Shen L...Zhu Y	32476607	2020
15	A case series describing the epidemiology and clinical characteristics of COVID-19 infection in Jilin Province. ⁶¹	Du N...Bao W	32441574	2020
16	Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. ⁶¹	Sun X...Zhang M	32338155	2020
17	What COVID-19 outbreak in Iran teaches us about virtual medical education. ⁶¹	Aghakhani K...Shalbafan M	32449487	2020
18	Diagnostic value and key features of computed tomography in Coronavirus Disease 2019. ⁶¹	Li B...Zhou Y	32241244	2020
19	Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster. ⁶¹	Xu Y...Wang M	32286155	2020
20	The coronavirus pandemic - A critical discussion of a tourism research agenda. ⁶¹	Zenker S...Kock F	32518437	2020
21	Medical students' dilemma during the Covid-19 pandemic; between the will to help and the fear of contamination. ⁶¹	Hjiej G...Fourtassi M	32578522	2020
22	Intersectionality as a lens to the COVID-19 pandemic: implications for sexual and reproductive health in development and humanitarian contexts. ⁶¹	Lokot M...Avakyan Y	32366190	2020
23	Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. ⁶¹	Bienvenu AL...Picot S	32562480	2020
24	Abortion in the context of COVID-19: a human rights imperative. ⁶¹	Todd-Gher J...Shah PK	32308156	2020
25	Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. ⁶¹	Sun B...Chen L	32357808	2020
26	Reproductive health under COVID-19 - challenges of responding in a global crisis. ⁶¹	Church K...Elliott M	32441213	2020
27	Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. ⁶¹	Dong J...Liu Y	32403995	2020
28	SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. ⁶¹	Yuen CK...Kok KH	32529952	2020
29	Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. ⁶¹	Lin L...Li T	32196410	2020
30	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. ⁶¹	Gelman R...Ilan Y	32490731	2020
31	Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. ⁶¹	Smither SJ...Lever MS	32496967	2020
32	Mathematic modeling of COVID-19 in the United States. ⁶¹	Tang Y...Wang S	32338150	2020
33	Family medicine in times of 'COVID-19': A generalists' voice. ⁶¹	de Sutter A...Editorial Board, Jelle Stoffers, Editor-in-Chief, the European Journal of General Practice	32349550	2020
34	Idle medical students review emerging COVID-19 research. ⁶¹	Boodman C...Bullard J	32441229	2020
35	Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. ⁶¹	Sun J...Li YM	32342724	2020
36	Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. ⁶¹	Xiong Y...Chen Y	32228226	2020
37	COVID-19: an FY1 on the frontline. ⁶¹	Jeyabaladevan P	32340566	2020
38	COVID-19: animals, veterinary and zoonotic links. ⁶¹	Tiwari R...Rodriguez-Morales AJ	32393111	2020
39	The impact of COVID-19 on the undergraduate medical curriculum. ⁶¹	Sandhu P...de Wolf M	32400298	2020
40	Nurse infected with Covid-19 from a provisional dengue patient. ⁶¹	Prasitsirikul W...Hemachudha T	32458742	2020
41	Clinical observation and management of COVID-19 patients. ⁶¹	Li T...Zhang W	32208840	2020
42	The impact of COVID-19 on the Neurosurgery practice in the North of Jordan. ⁶¹	Al Barbarawi MM...Alomari AA	32537423	2020
43	Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. ⁶¹	Liu P...Xu J	32515685	2020
44	COVID-19: time for a bold new strategy for medical education. ⁶¹	Watson A...Green CA	32400295	2020
45	Eco-epidemiological assessment of the COVID-19 epidemic in China, January-February 2020. ⁶¹	Byass P	32404043	2020
46	The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. ⁶¹	Su L...Gai Z	32208917	2020
47	The role of asymptomatic class, quarantine and isolation in the transmission of COVID-19. ⁶¹	Ali M...Khan A	32498655	2020
48	Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China. ⁶¹	Liu XH...Lu HZ	32515651	2020
49	Patterns of IgG and IgM antibody response in COVID-19 patients. ⁶¹	Liu X...Hu CH	32515684	2020
50	Perspectives from a webinar: COVID-19 and sexual and reproductive health and rights. ⁶¹	MacKinnon J...Bremshey A	32354272	2020

Sources

Genes for Covid-19

Genes related to Covid-19 (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ACE2	Angiotensin I Converting Enzyme 2	Protein Coding	27.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
2	TMPRSS2	Transmembrane Serine Protease 2	Protein Coding	23.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
3	DPP4	Dipeptidyl Peptidase 4	Protein Coding	22.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
4	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	21.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
5	CTSL	Cathepsin L	Protein Coding	21.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
6	LOC117134608	TMPRSS2 Androgen Receptor-Responsive -13 Kb Enhancer	Biological Region	15.9	GeneCards inferred via : Publications Summaries (show sections)
7	LOC117135106	TMPRSS2 Androgen Receptor-Responsive -60 Kb Enhancer	Biological Region	15.9	GeneCards inferred via : Publications Summaries (show sections)
8	LOC117134604	TMPRSS2 Promoter Region	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
9	LOC117134605	TMPRSS2 Repressive Element NBS1	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
10	LOC117134606	TMPRSS2 Repressive Element NBS2	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
11	LOC117134607	TMPRSS2 Repressive Element NBS4	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
12	LOC117134611	TMPRSS2 -17 Kb Enhancer	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
13	LOC117135104	TMPRSS2 E3 Enhancer	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
14	LOC117135105	TMPRSS2 E4 Enhancer	Biological Region	15.71	GeneCards inferred via : Publications Summaries (show sections)
15	CRP	C-Reactive Protein	Protein Coding	14.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	IL6	Interleukin 6	Protein Coding	14.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	ACE	Angiotensin I Converting Enzyme	Protein Coding	13.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	FURIN	Furin, Paired Basic Amino Acid Cleaving Enzyme	Protein Coding	13.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	CD8A	CD8a Molecule	Protein Coding	12.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	AGTR2	Angiotensin II Receptor Type 2	Protein Coding	12.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	12.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Covid-19

Sources

Expression for Covid-19

Search GEO for disease gene expression data for Covid-19.

Sources

Pathways for Covid-19

Pathways related to Covid-19 according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Hematopoietic cell lineage ³⁶	11.13	IL6 IL2RA CD8A
2	Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE Inhibitor Pathway ¹ ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Renin-angiotensin system ³⁶	10.7	AGTR2 ACE2 ACE

Sources

GO Terms for Covid-19

Cellular components related to Covid-19 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.28	TMPRSS2 IL6 FURIN DPP4 CTSL CRP

Biological processes related to Covid-19 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	proteolysis	GO:0006508	9.43	TMPRSS2 FURIN DPP4 CTSL ACE2 ACE
2	angiotensin maturation	GO:0002003	9.37	ACE2 ACE
3	negative regulation of lipid storage	GO:0010888	9.32	IL6 CRP
4	neutrophil mediated immunity	GO:0002446	9.26	IL6 ACE
5	regulation of systemic arterial blood pressure by renin-angiotensin	GO:0003081	9.16	ACE2 ACE
6	regulation of blood vessel diameter	GO:0097746	8.8	AGTR2 ACE2 ACE

Molecular functions related to Covid-19 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endopeptidase activity	GO:0004175	9.5	FURIN ACE2 ACE
2	peptidase activity	GO:0008233	9.43	TMPRSS2 FURIN DPP4 CTSL ACE2 ACE
3	exopeptidase activity	GO:0008238	9.26	ACE2 ACE
4	peptidyl-dipeptidase activity	GO:0008241	9.16	ACE2 ACE
5	dipeptidyl-peptidase activity	GO:0008239	8.8	DPP4 ACE2 ACE

Sources

Sources for Covid-19

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia